Expression of blood hepatocyte-derived microRNA-122 in canine multicentric lymphoma with hepatic involvement

Ramadan, Eman; Kubesy, A. A.; Baraka, Taher; Torad, Faisal A.; Salem, Shaymaa I.; Salem, Noha Y.

doi:10.1007/s11259-019-09764-w

Cited by 8 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in human medicine have shown characteristic expression pro les of miRNA in tumors [13]. MicroRNAs (miRNAs) are clusters of small non-coding RNA that play an essential part in posttranscriptional gene expression as imperative regulators [14,15]. Several miRNA species have been identi ed to be involved in human breast cancer development, including miR-21, miR-145, and miR-210 [16][17][18].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors

et al. 2021

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors

et al. 2021

Self Cite

View full text Add to dashboard Cite

“…The increase in cfa‐miRNAs‐122 and‐21 in serum can be caused by injury to other nonhepatic tissues, such as colonic injuries in dogs with inflammatory bowel disease 39 . There are also other causes of liver injury that can increase serum miRNA‐122 in dogs such as multicentric lymphoma, 40 hepatic carcinoma, 41 and acute hepatitis 42 . Therefore, more advanced future studies are required to better understand the functions of these miRNAs.…”

Section: Discussionmentioning

confidence: 99%

Hepatocyte‐derived canine familiaris‐microRNAs as serum biomarkers of hepatic steatosis or fibrosis as implicated in the pathogenesis of canine cholecystolithiasis

El-Sebaey

Abramov

2021

Veterinary Clinical Pathol

View full text Add to dashboard Cite

Background Hepatic cholesterol accumulation in small breed dogs is a leading risk factor for hepatic fatty changes, gallbladder hypomotility, and cholelith development, which, if not discovered early, could lead to life‐threatening choledocholithiasis and acute pancreatitis. Objective This study proposed to assess the use of hepatocyte‐derived canine familiaris (cfa)‐microRNAs (miRNA‐122, ‐34a, and ‐21) as new diagnostic serum biomarkers of liver steatosis or fibrosis, for which both processes have been implicated in canine cholecystolithiasis. Methods Forty client‐owned dogs diagnosed with cholecystolithiasis and hepatic steatosis (C+HS) or fibrosis (C+HF) based on ultrasonographic, biochemical, and histopathologic findings, and 20 healthy dogs used as controls were included in the study. Serum cfa‐miRNA expression was determined using a real‐time polymerase chain reaction assay. Results Serum cfa‐miRNA‐122 and −34a expression was significantly upregulated in the C+HS (P < .001) and C+HF (P < .01) groups compared with the control group and showed a positive correlation with alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), alkaline phosphatase (ALP), γ‐glutamyl transferase (GGT), total cholesterol (TC), and triglycerides (TG) levels in the C+HS group. Cfa‐miRNA‐122 and −34a expression discriminated the diseased groups from the control group better than traditional serum‐derived liver biomarkers, as evidenced by areas under the receiver operating characteristic (AUC‐ROC) curve of 0.99 and 0.97 for cfa‐miRNA‐122 expression in the C+HS and C+HF groups, and 1.0 and 0.96 for cfa‐miRNA‐34a in the C+HS and C+HF groups, respectively. Cfa‐miRNA‐21 expression was upregulated only in the C+HF group compared with the C+HS (P < .01) and control (P < .001) groups and showed a positive correlation with serum ALT, AST, TBIL, ALP, and GGT and negative correlation with serum TC and TG levels. Cfa‐miRNA‐21 expression could also differentiate the C+HF group from the control and C+HS groups with a diagnostic performance superior to that of the conventional serum biochemical variables as evidenced by AUCs of 1.0 and 0.98, respectively. Conclusions Serum cfa‐miRNA‐122, ‐34a, and ‐21 expression was significantly upregulated in dogs with cholecystolithiasis with hepatic steatosis or fibrosis compared with control dogs. These miRNAs could serve as novel biomarkers for hepatic steatosis or fibrosis, which have been implicated in the pathogenesis of cholecystolithiasis.

show abstract

“…They usually exhibit the great potential to address some of the significant limitations described for serum biochemical markers of liver injuries [ 11 ]. Also, they can even outperform serum ALT values as sensitive, specific, and predictive hepatic biomarkers in dogs [ 12 , 36 , 37 ] and human models [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Clinical Characteristics, Serum Biochemical Changes, and Expression Profile of Serum Cfa-miRNAs in Dogs Confirmed to Have Congenital Portosystemic Shunts Accompanied by Liver Pathologies

El-Sebaey

Abramov

Abdelhamid

2020

Veterinary Sciences

View full text Add to dashboard Cite

Computed tomography angiography (CTA) and biochemical parameters cannot specify liver pathologies in dogs with congenital portosystemic shunts (CPSS) that are easily determined by invasive histopathology. This study aims to assess the possibility of using circulating serum canine familiaris (cfa) microRNAs (miRNAs) as novel non-invasive serum-based fingerprints for liver injuries associated with various morphologies of extrahepatic and intrahepatic portosystemic shunts (EHPSS and IHPSS). Data were obtained from 12 healthy dogs and 84 dogs confirmed to have EHPSS (splenocaval, splenophrenic, splenoazygos, right gastrocaval (RGC), right gastrocaval with caudal loop (RGC–CL)) and IHPSS (right divisional and left divisional) using CTA. Hepatic pathologies were determined by histopathology. Serum expression of miRNAs was assessed by real-time polymerase chain reaction. Based on the nature of liver injuries in each shunt type, cfa-miR-122 was significantly upregulated in all CPSS groups. Meanwhile, serums cfa-miR-34a and 21 were not significantly expressed in splenophrenic or splenoazygos groups, but they were extensively upregulated in splenocaval, RGC, RGC–CL groups and less frequently in right or left divisional groups. Also, serum cfa-miR126 was significantly upregulated in both IHPSS groups but less significantly expressed in RGC, RGC–CL, and splenocaval groups. Overall, estimated cfa-miRNAs could serve as novel biomarkers to mirror the histopathological and molecular events within the liver in each shunt type.

show abstract

Expression of blood hepatocyte-derived microRNA-122 in canine multicentric lymphoma with hepatic involvement

Cited by 8 publications

References 38 publications

MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors

MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors

Hepatocyte‐derived canine familiaris‐microRNAs as serum biomarkers of hepatic steatosis or fibrosis as implicated in the pathogenesis of canine cholecystolithiasis

Clinical Characteristics, Serum Biochemical Changes, and Expression Profile of Serum Cfa-miRNAs in Dogs Confirmed to Have Congenital Portosystemic Shunts Accompanied by Liver Pathologies

Contact Info

Product

Resources

About